<DOC>
	<DOCNO>NCT00719381</DOCNO>
	<brief_summary>The purpose study determine effect pioglitazone reduce airway inflammation cystic fibrosis characterize amount timecourse pioglitazone elimination body .</brief_summary>
	<brief_title>Effect Pioglitazone Inflammation Cystic Fibrosis</brief_title>
	<detailed_description>Progressive loss lung function due chronic infection inflammation primary cause morbidity mortality patient CF . Current therapy direct treatment chronic P. aeruginosa infection ( e.g . aerosolize tobramycin , azithromycin ) provide short-term improvement pulmonary function ; however , persistence infection/inflammation cause inevitable loss lung function . PPARgamma nuclear transcription factor know reduce activation NFKB , central mediator airway inflammation CF . Recent study demonstrate PPARgamma expression reduce patient CF may offer potential therapeutic target combat airway inflammation CF . Pioglitazone thiazolidinedione whose principal pharmacological target PPARgamma . The purpose pilot study determine pharmacokinetics/pharmacodynamics pioglitazone effect reduce airway inflammation cystic fibrosis .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Age great 18 year Clinically stable ( FEV1 within 10 % baseline ) FEV1 &gt; 40 % predict History hypoglycemic event Hepatic disease ( AST , ALT &gt; 2.5x ULN ) Renal disease ( GFR &lt; 60 ml/min 1.73m2 ) Currently receive betablocker , oral corticosteroid , statin , angiotensin receptor blocker , trimethoprimsulfamethoxazole , gemfibrozil , rifampin therapy . Allergy thiazolidinediones Pregnancy attempt conceive , breast feeding Hematocrit &lt; 30 Congestive heart failure Pulmonary hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>